There are currently 56 clinical trials in Centennial, Colorado looking for participants to engage in research studies. Trials are conducted at various facilities, including Rocky Mountain Cancer Centers - Centennial, IMMUNOe Research Centers, Teva Investigational Site 1090 and IMMUNOe International Research Centers. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA
NCT05820672
Recruiting
The goal of this study is to genrate evidence on long-term effectiveness and safety of SKYTROFA (lonapegsomatropin) in patients with growth hormone deficiency under routine clinical care
Gender:
All
Ages:
Between 1 year and 18 years
Trial Updated:
04/15/2024
Locations: Ascendis Pharma Investigational Site, Centennial, Colorado
Conditions: Growth Hormone Deficiency
Register for Updates
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NCT03723928
Recruiting
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/03/2024
Locations: Rocky Mountain Cancer Centers - Centennial, Centennial, Colorado
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
Register for Updates
MiSight 1 Day Safety Post-Approval Study
NCT05285527
Recruiting
The purpose of this post-approval study is to confirm the safety of daily disposable soft contact lens wear among the intended patient population for the MiSight 1 Day lens in the US.
Gender:
All
Ages:
Between 8 years and 12 years
Trial Updated:
03/14/2024
Locations: Children's Eye Physicians, Centennial, Colorado
Conditions: Myopia
Register for Updates
Intravesical BCG vs GEMDOCE in NMIBC
NCT05538663
Recruiting
The study hypothesis is that BCG naïve non-muscle invasive bladder cancer (NMIBC) patients treated with intravesical Gemcitabine + Docetaxel (GEMDOCE) will result in a non-inferior event-free survival (EFS) compared to standard treatment with intravesical BCG. The purpose of this study is to test whether Gemcitabine + Docetaxel is a better or worse treatment than the usual BCG therapy approach. The primary objective of this study is to determine the event free survival (EFS) of BCG-naïve high gr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: Rocky Mountain Cancer Centers - Centennial, Centennial, Colorado
Conditions: Non-muscle-invasive Bladder Cancer
Register for Updates
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
NCT05505916
Recruiting
This is an open-label, multicenter extension trial to evaluate the long-term safety of KVD900 in patients who are 12 years or older with HAE type I or II.
Gender:
All
Ages:
12 years and above
Trial Updated:
03/06/2024
Locations: KalVista Investigative Site, Centennial, Colorado
Conditions: Hereditary Angioedema
Register for Updates
PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
NCT05511922
Recruiting
This is a multicenter pharmacokinetic (PK) subtrial to investigate the PK profile of KVD900 in adolescent patients 12 to 17 years of age with Hereditary Angioedema (HAE) type I or II.
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
03/06/2024
Locations: KalVista Investigative Site, Centennial, Colorado
Conditions: Hereditary Angioedema
Register for Updates
Comparison of Methods in Post Operative Knee Arthroscopy Rehabilitation
NCT05735236
Recruiting
The aim of this study is to investigate the efficacy of blood flow restriction (BFR) therapy in post operative rehabilitation following knee arthroscopy.
Gender:
All
Ages:
Between 16 years and 60 years
Trial Updated:
02/15/2024
Locations: UCHealth Steadman Hawkins Clinic, Centennial, Colorado
Conditions: Muscle Weakness, Muscle Atrophy
Register for Updates
Phase 2b Study of ALTO-100 in MDD
NCT05712187
Recruiting
The purpose of this study is to determine efficacy differences between ALTO-100 and placebo, used either as monotherapy or adjunctively to an antidepressant, related to patient characteristics.
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
01/10/2024
Locations: Site 185, Centennial, Colorado
Conditions: Major Depressive Disorder
Register for Updates
A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin
NCT05775523
Recruiting
The goal of this study is to further characterise the potential long-term safety risks of lonapegsomatropin in patients treated with lonapegsomatropin under real-world conditions in the post-marketing setting.
Gender:
All
Ages:
Between 1 year and 18 years
Trial Updated:
01/09/2024
Locations: Ascendis Pharma Investigational Site, Centennial, Colorado
Conditions: Growth Hormone Deficiency
Register for Updates
A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD
NCT05721235
Recruiting
The is a multicenter, dose-optimized, open-label, safety/ tolerability and pharmacokinetic (PK) study with Azstarys® in children 4 and 5 years of age with attention-deficit/hyperactivity disorder (ADHD). The primary objective is to determine the safety and tolerability of treating children 4 and 5 years-of-age with ADHD with Azstarys® for up 12 months. Approximately 100 subjects will be enrolled. Approximately 20 sites will participate.
Gender:
All
Ages:
Between 4 years and 5 years
Trial Updated:
01/04/2024
Locations: IMMUNOe International Research Center, Centennial, Colorado
Conditions: Attention Deficit/Hyperactivity Disorder
Register for Updates
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
NCT05677490
Recruiting
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by k... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/30/2023
Locations: Rocky Mountain Cancer Centers - Centennial, Centennial, Colorado
Conditions: Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
Register for Updates
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
NCT04511013
Recruiting
This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Ipilimumab and nivolumab are monoclonal antibodies that may interfere with the ability of tumor cells to grow and spread. This trial aims to find out which approach... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/11/2023
Locations: Rocky Mountain Cancer Centers - Centennial, Centennial, Colorado
Conditions: Acral Lentiginous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Metastatic Mucosal Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
Register for Updates